How Much Money Has Pfizer Made From The COVID-19 Vaccine? | By The Numbers

The question on everyone’s mind is simple: how much cash did Pfizer bring in from its COVID-19 shot, Comirnaty? Below, you’ll get the short, factual answer up top, then a clean breakdown of year-by-year revenue, what “made” means in finance terms (revenue vs. profit), and the accounting quirks that explain why the numbers move. No fluff—just the figures and the context to read them well.

Comirnaty Money Snapshot (Quick Table)

This table assembles the headline numbers and key context you need before diving deeper.

Item	Figure Or Fact	Context
2021 Revenue	$36.781B	First full commercial year after late-2020 authorization.
2022 Revenue	$37.806B	Peak demand across boosters and global contracts.
2023 Revenue	$11.220B	Post-emergency transition; demand eased sharply.
2024 Revenue	$5.353B	Commercial market era; seasonal boosters.
Total 2021–2024	~$91.2B	Sum of reported Comirnaty revenue at Pfizer.
Profit Share	50% gross profit split	Paid to BioNTech; booked in “cost of sales.”
U.S. Private Price	$110–$130/dose	Range quoted for the commercial market period.
Write-offs & Deferrals	Present in 2023–2024	Inventory charges and timing can swing results.

Pfizer Covid-19 Vaccine Revenue—Year-By-Year

Here’s the straight readout from Pfizer’s own reporting, with each year’s figure rounded to the nearest million. These are Pfizer’s Comirnaty revenues (direct sales plus alliance revenue where applicable), not BioNTech’s.

2021: Breakout Year

Pfizer recorded $36.781 billion from Comirnaty in 2021. This was the first full commercial year after late-2020 emergency authorizations, as supply scaled and large contracts landed.

2022: Peak Sales

Comirnaty delivered $37.806 billion in 2022, the high-water mark. Booster campaigns and global deliveries kept the tally elevated before the later shift to a commercial seasonal model.

2023: The Post-Emergency Reset

Pfizer reported $11.220 billion from Comirnaty in 2023. The U.S. moved to a traditional commercial market, vaccination rates cooled, and COVID product demand normalized. The company also booked COVID-related write-offs and timing items that affected reported results.

2024: Commercial Market Era

For 2024, Comirnaty revenue landed at $5.353 billion, reflecting a seasonal booster business that’s smaller than the emergency-contract phase but still meaningful inside Pfizer’s broader portfolio.

What That Adds Up To

Across 2021–2024, that’s about $91.2 billion in Pfizer-reported revenue from the COVID-19 vaccine. This is the best apples-to-apples way to answer “How much money has Pfizer made from the COVID-19 vaccine?” in public company terms: revenue recognized by Pfizer for Comirnaty across those years.

How Much Money Has Pfizer Made From The COVID-19 Vaccine? (Recap)

In common speech, “made” can mean revenue or profit. In finance, those are very different. The exact keyword—how much money has Pfizer made from the COVID-19 vaccine?—is best answered as revenue first, then profit context:

• Revenue is the sum of recognized sales and alliance revenue. That’s the ~$91.2B figure.
• Profit comes after costs, including a 50% gross profit split to BioNTech on Pfizer-territory sales, plus manufacturing, distribution, royalties, taxes, and operating expenses. Profit is necessarily lower than revenue and varies by quarter and year.

Revenue Vs. Profit: What “Made” Really Means

When headlines say a company “made” $X, they often mean revenue. Pfizer’s reporting makes clear that Comirnaty revenue includes direct sales and alliance revenue across allocated territories, while a gross profit share is paid to BioNTech. That share runs through “cost of sales,” which is why the company’s cost-of-sales percentage jumped during the vaccine’s peak years. After that, operating expenses and taxes further reduce the bottom line.

So, reading the stacked income statement:

1. Top line: Comirnaty revenue is recognized as contracts deliver.
2. Next: cost of sales includes the profit split and production costs.
3. Then: selling, general, and R&D expenses.
4. Finally: taxes and other income/deductions determine net income.

Why The Numbers Shift Year To Year

1) Demand Cycles

Emergency-phase mass supply gave way to seasonal boosters. That alone explains the arc from ~<$40B in 2021–2022 to single-digit billions by 2024.

2) Contract Timing

Government contracts front-loaded revenue during the public health emergency; later, orders shifted to retail and payers with a more typical seasonal cadence.

3) Pricing

In the commercial period, Pfizer indicated a U.S. price range of about $110–$130 per dose. Doses, channels, and payer mixes then determine realized revenue.

4) Accounting Items

Deferred revenue, write-offs for expired doses, and revisions to supply agreements—all of these can move reported figures even when underlying demand looks similar.

How Pfizer Accounts For The Vaccine (Cheat Sheet)

These are the accounting mechanics that shape what you see in the earnings tables. They’re simple once you translate the jargon.

Line Item	What It Means	Why It Matters
Direct Sales	Pfizer sells doses in its allocated territories.	Feeds the top-line revenue you see each year.
Alliance Revenue	Revenue under the BioNTech partnership model.	Included in Comirnaty revenue; varies by territory split.
Cost Of Sales	Includes production plus 50% gross profit split to BioNTech.	Explains the higher cost-of-sales percentage in vaccine years.
Deferred Revenue	Billed/contracted but recognized later upon delivery.	Creates timing gaps that smooth out in later quarters.
Write-offs/Reserves	Charges for expired or excess inventory, or contract updates.	Can pull reported results down in low-demand periods.
Operating Expenses	Sales, administration, and ongoing R&D.	Beyond cost of sales, these shape operating profit.
Taxes & Other	Taxes plus gains/losses and other items.	Final step from operating profit to net income.

Where The Partnership Fits

Pfizer and BioNTech split geographies and share economics. Pfizer recognizes Comirnaty revenue for its territories and pays a 50% gross profit share to BioNTech on those sales. BioNTech, in turn, books its share in “commercial revenues” and reports it separately to shareholders. This structure is standard for co-development deals and is the main reason revenue and profit move differently.

How To Read The $91.2B Total Responsibly

Two good rules of thumb keep the figure grounded:

• Revenue ≠ profit. The 50% profit share and manufacturing logistics meaningfully reduce what lands at the bottom line.
• Totals reflect timing. Some deliveries land just after year-end, so revenue recognition can slide from December into the next fiscal year. That’s normal under the rules.

Helpful Source Links

For a quick primary-source view, see the Pfizer 2023 Annual Report performance PDF (shows 2023 top products, including Comirnaty) and the 2024 Annual Review top-products page (lists 2024 Comirnaty revenue). These two snapshots capture the post-emergency reset well.

Method, Scope, And Constraints

This piece totals Pfizer-reported Comirnaty revenue for 2021–2024 and presents it alongside notes on how the collaboration and accounting work. Figures are taken from Pfizer’s own annual reviews, earnings materials, and filings. Profit is not estimated here because the profit share, inventory charges, and period-specific expenses can swing results; Pfizer and BioNTech report those line items separately in detail.

Bottom Line On Pfizer’s Vaccine Money

Using Pfizer’s reported numbers, Comirnaty generated about $91.2 billion in revenue from 2021 through 2024. The partnership structure means Pfizer does not keep that entire sum: half the gross profit goes to BioNTech, and the usual costs and taxes apply. If you came looking for the fast, defensible answer to “how much money has Pfizer made from the COVID-19 vaccine?”, the revenue tally above is the cleanest way to state it—and the sections here give you the tools to read that number correctly.